Tuesday September 26, 2017 10:51

Heathcare Press Release : 06 Mar 2017

LEO Pharma Announces Positive Results From Phase 2b Clinical Study for Tralokinumab in Atopic Heathcare—06 Mar 17

LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational